This serious disease affects the unborn child, blood transfusion is required

A new drug has excited scientists to treat a serious pregnancy-related disease called hemolytic anemia (HDFN). This disease causes severe anemia in the child due to different blood groups of the mother and the child. Till now, to treat this disease, the child had to be given blood transfusion in the womb itself, which was very risky. But now its treatment will become easier.

What is hemolytic anemia?

Hemolytic anemia is a condition in which the body destroys red blood cells at a faster rate than normal. During pregnancy, if the mother and baby have different blood types, the mother's body may make antibodies against the baby's red blood cells. These antibodies destroy the baby's red blood cells, causing severe anemia in the baby.

Treatment will be easy with this medicine

Nipocalimab is a drug that prevents the transfer of harmful antibodies across the placenta. This protects the baby's red blood cells and reduces the risk of anemia.

What did the research reveal?

Scientists at the University of Texas tested this drug on 13 pregnant women whose fetuses had previously died due to HDFN or who had to undergo a blood transfusion. The study found that 54% of the women who took this drug gave birth to a healthy baby without a blood transfusion.

What are the advantages of the drug Nipocalimab?

This reduces the need for blood transfusion inside the uterus.

This reduces the risk of fetal death and premature birth.

This prevents serious conditions like hydrops in the fetus.